Voyager Acquisition is a SPAC — a blank check company with no operations — formed solely to merge with a private company and take it public. Voyager raised $253M in its August 2024 IPO, with proceeds held in trust. The company focuses on healthcare broadly defined, including life sciences, medical devices, diagnostics, digital health, and healthcare services. Voyager has a pending deal: in April 2025, it signed a Business Combination Agreement to merge with Veraxa Biotech AG, a Swiss biotech company, at an implied merger consideration of approximately $1.35B. The transaction is expected to close in early 2026, subject to shareholder approval. SPACs like Voyager generate returns for their sponsors through founder shares — acquired at a nominal cost and representing roughly 20% of the post-IPO share count — which convert into equity in the combined public company if a deal closes. This creates an inherent incentive for the sponsor to close a deal before the 24-month deadline, which Voyager explicitly acknowledges as a conflict of interest. If no deal closes, the trust is liquidated and public shareholders receive approximately $10.05 per share, while the sponsor's founder shares and warrants expire worthless. Each IPO unit included a half-warrant exercisable at $11.50, which can be dilutive post-merger. Voyager's filing provides no detail on Veraxa's pipeline or financials; investors evaluating the target would need to review Veraxa's separate disclosures.